Trials / Unknown
UnknownNCT02186574
Tenofovir to Prevent HBV Reactivation
A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 184 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's Lymphoma or CLL/SLL. The rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir disoproxil | |
| DRUG | Placebo Oral Tablet |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2014-07-10
- Last updated
- 2019-12-12
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02186574. Inclusion in this directory is not an endorsement.